产品
编 号：F182793
分子式：C14H15N3O
分子量：241.29
分子式：C14H15N3O
分子量：241.29
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
结构图
CAS No: 154235-83-3
产品详情
生物活性：
CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI).
体内研究：
The specific extradimensional deficits produced by sub-chronic or early postnatal postnatal phencyclidine treatment were significantly attenuated by CX516 (10, and 20 mg/kg, s.c.).Animal Model:Male Lister Hooded rats (56-63 postnatal day)
Dosage:5, 10, 20, and 40 mg/kg
Administration:Subcutaneously
Result:Two doses (10 and 20 mg/kg) were highly significant in improving the extradimensional shift deficit induced by either treatment regimes. Two doses (5 and 40 mg/kg) was ineffective at reversing the extradimensional impairment induced by the sub-chronic postnatal phencyclidine treatment regime.
CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI).
体内研究：
The specific extradimensional deficits produced by sub-chronic or early postnatal postnatal phencyclidine treatment were significantly attenuated by CX516 (10, and 20 mg/kg, s.c.).Animal Model:Male Lister Hooded rats (56-63 postnatal day)
Dosage:5, 10, 20, and 40 mg/kg
Administration:Subcutaneously
Result:Two doses (10 and 20 mg/kg) were highly significant in improving the extradimensional shift deficit induced by either treatment regimes. Two doses (5 and 40 mg/kg) was ineffective at reversing the extradimensional impairment induced by the sub-chronic postnatal phencyclidine treatment regime.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备